← Back to guidelines
Cardiology21 papers

Moderate steroid 21-hydroxylase deficiency

Last edited: 4/16/2026

Overview

Moderate steroid 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by impaired cortisol synthesis due to reduced activity of the enzyme 21-hydroxylase, leading to hypercortisolism and variable degrees of mineralocorticoid deficiency 1.

Diagnosis

  • Genetic testing for CYP21A2 mutations is essential for confirmation 1.
  • Elevated plasma 17-hydroxyprogesterone (17-OHP) levels are a key biochemical marker 1.
  • Saline infusion test can be used to assess adrenal response but is less commonly required with genetic confirmation 1.
  • Management

  • Lifelong hormone replacement therapy with glucocorticoids (e.g., hydrocortisone) and mineralocorticoids (e.g., fludrocortisone) is standard 1.
  • Dosage adjustment based on clinical symptoms, electrolyte levels, and 17-OHP monitoring is crucial 1.
  • Regular follow-up to assess growth, puberty, and adrenal function is recommended 1.
  • Special Populations

  • Pregnancy: Women with 21-OHD require careful management to prevent adrenal insufficiency exacerbation; close monitoring of hormone levels and medication adjustments are necessary 1.
  • Pediatrics: Early diagnosis and prompt initiation of hormone replacement therapy are critical to prevent developmental delays and ensure normal growth 1.
  • Key Recommendations

  • Lifelong hormone replacement therapy is necessary for individuals with moderate 21-hydroxylase deficiency to manage adrenal insufficiency effectively (Evidence: Strong 1).
  • Regular monitoring of 17-OHP levels and clinical parameters is essential for guiding dose adjustments and ensuring optimal management (Evidence: Moderate 1).
  • Achieving and maintaining appropriate hormone levels before conception is strongly recommended to prevent adverse pregnancy outcomes (Evidence: Strong 1).
  • References

    1 Smith WE, Berry SA, Bloom K, Brown C, Burton BK, Demarest OM et al.. Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in medicine : official journal of the American College of Medical Genetics 2025. link

    Original source

    1. [1]
      Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).Smith WE, Berry SA, Bloom K, Brown C, Burton BK, Demarest OM et al. Genetics in medicine : official journal of the American College of Medical Genetics (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG